复宏汉霖启动HLX22对比一线疗法治疗HER2阳性晚期胃癌的III期临床研究,全球多中心进行,已完成美国首例患者给药,该疗法有望填补胃癌治疗空白。
Source Link复宏汉霖启动HLX22对比一线疗法治疗HER2阳性晚期胃癌的III期临床研究,全球多中心进行,已完成美国首例患者给药,该疗法有望填补胃癌治疗空白。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.